Professional Documents
Culture Documents
n e w s
Falsely elevated blood glucose readings with Extraneal peritoneal dialysis solution
ISSN: 0219 2152 July 2005 Vol.7 No.2
Extraneal (Baxter) is a brand of peritoneal dialysis solution that contains icodextrin. Icodextrin is a glucose polymer that is broken down into maltose in the body. The accumulation of blood maltose can interact with glucose monitoring systems that are not glucosespecific (e.g. those using the GDH-PQQ method) and give rise to falsely elevated glucose readings. As a result, the patient may receive an excessive dose of insulin leading to a hypoglycaemic episode. On the other hand, cases of hypoglycaemia might not be treated if their hypoglycaemic states are masked by glucose readings that are falsely elevated into the normal range.
Overestimation of blood glucose may result in inappropriate administration of insulin or mask hypoglycaemia
There have been recent overseas adverse reports of patient injuries caused by falsely elevated blood glucose readings in diabetic patients who were using peritoneal dialysis solution that contains icodextr in and blood glucose monitor ing systems that are based on the glucose dehydrogenasepyrroloquinolinequinone (GDHPQQ) method. Some of the cases were fatal. Such drug-device interaction may falsely elevate the capillary blood glucose level readings by 3.6 1.4 mmol/l (1) compared to laboratory venous blood glucose measurements when the GDP-PQQ based glucometers are used (normal fasting glucose: 6.1 8.0 mmol/l). Preventive measures To reduce the risk of the above drug-device interaction, the following preventive measures are recommended: Diabetic patients who require dialysis and are prescribed Extraneal should be issued with a Safety Alert Card provided by Baxter (the manufacturer of Extraneal). Patients should be advised to present this card to any attending medical personnel should
he/she require any medical attention e.g. at the A&E departments in hospitals. Patients on Extraneal should use only glucose-specific glucometers that are not affected by icodextrin metabolites. Patients should be given specific instructions on the appropriate type of home blood glucometer that they should use and they should verify the suitability of the glucometers with the company distributing it. The existing brands of GDH-PQQ based glucometers that should not be used by patients on Extraneal include FreeStyle Papillon and Accu-Chek Active/ Advantage/ Compact/ Complete/ Go. Patients should be advised to read the product information leaflet of the glucose monitoring system before using them.
news
contents
Elevated blood glucose meter readings with Extraneal Case reports of serious ADRs associated with adulterated complementary medicines Labelling changes Safety update Visual disorders & erectile dysfunction drugs Highlights on COX-2 selective & non-selective NSAIDs 01
Published by the Centre for Drug Administration, HSA and the Pharmacovigilance Advisory Committee
02
04
05
06
Reporting Made Easy: Online adverse drug reaction reporting is available at http://www.hsa.gov.sg/ADR_online
The Pharmacovigilance Unit, HSA has been receiving adverse reaction reports from our healthcare professionals that are suspected to be associated with the use of complementary medicines. Further investigations revealed that a number of these products had been adulterated with western drugs. Many of these products were obtained by consumers from overseas sources or local peddlers who had brought the products from overseas. Although many of these products are not sold in local retail outlets, HSA has recently issued a press release
on five adulterated products to alert members of the public (see http://www.hsa.gov.sg/html/corporate/pressreleases.html for press release). Healthcare professionals play an important role in helping HSA detect potential adulterated complementary medicinal products as evidenced by the case reports summarised below. Healthcare professionals are encouraged to enquire about complementary medicine use in their patients especially products that have been consumed in the recent three months when they suspected an adverse drug reaction.
Jamu Pegal Linu, product of PJ. Guna Sehat Suryo Sudarmo from Cilacap Indonesia - For body ache, rheumatism, blurred vision, disability, stroke and lethargy.
Malay, male with severe neutropenia and consequent necrotising fasciitis. Adulterants found (per packet): Dipyrone 25.7 mg and phenylbutazone 6.1 mg. [Recommended dose: 2 packets/day.]
Ramuan Tradisional Madura, product of CV. Wahyu Ilahi, formulated by K Saum/H Murais, Indonesia - Asthma, rheumatism, high blood pressure, diabetes, kidney stone, tumour, migraine, liver, allergy, gastric, weak heart/heart failure, eczema, lack of appetite, low blood volume, sexual impotency, gout.
Malay, male with with hepatitis B flare-up. Adulterant found: Dexamethasone 0.032 mg/g or 0.166 mg/day (based on daily recommended dose).
Kapsul Asam Urat (TCU), product of Prananda Jaya Sukses from Indonesia - For ner ve pain, waist pain, rheumatism, stiff muscle, leg swelling, listlessness and insomnia.
Adulterants found (per capsule): Pa ra c e t a m o l 1 7 3 . 3 2 m g a n d phenylbutazone 89.73 mg. [Recommended dose: 4 capsules/day.]
Adulterants found (per capsule): Chlor pheniramine 1.73 mg, chloramphenicol 105.74 mg, ibuprofen 274.97 mg and tetracycline 53.37 mg. [Recommended dose: 2 capsules/day.]
Phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (Viagra, Pfizer), vardenafil (Levitra, Bayer) and tadalafil (Cialis, Eli Lilly), are known to cause reversible and transitory visual disorders such as blurred vision and increased sensitivity to light in some patients. These visual abnormalities are related to the inhibition of PDE6 enzyme that is involved in the phototransduction pathway of the retina.
both eyes affected. All affected patients had at least one arteriosclerotic risk factors including hypertension, diabetes, elevated cholesterol or hyperlipidaemia. The dose of sildenafil was either 25 mg, 50 mg or 100 mg. Some had been taking the drug intermittently for months or years for the treatment of erectile dysfunction while others had only used one or a few doses before the occurrence of visual loss. Visual field loss was present in all patients, as was optic disc oedema in the affected eye, often with associated nerve fiber layer haemorrhages. In a previous report by the same author, another five patients (aged between 42 and 69 years old) developed NAION subsequent to ingestion of Viagra and the reported time of occurrence of visual disorder was similar to the above study. (2) All the 12 patients in both reports had optic discs with small cup-to-disk ratios in the unaffected eye. Isolated cases of NAION have been reported with the use of tadalafil. The patients experienced visual field defect within hours to days of tadalafil 20 mg ingestion (3,4).
Comments
The mechanism for NAION is not established. It is not possible at this point to determine whether these events are related directly to the use of PDE5 inhibitors, to the patients underlying vascular risk factors or anatomical defects, to a combination of these factors, or to other factors. Physicians prescribing sildenafil or related drugs to patients with ischaemic risk factors of hypertension, diabetes mellitus, increased serum cholesterol or lipids may wish to alert patients on the potential risk of visual loss with this medication until further clinical experience is obtained. Patients should be advised to stop the use of any PDE5 inhibitors and seek medical attention in the event of a sudden loss of vision in one or both eyes. Physicians are also encouraged to ask patients with NAION about the use of sildenafil or related drugs and to report any suspected serious ADRs to the Pharmacovigilance Unit of HSA.
References: 1. Journal of Neuro-Ophthalmology 2005; 25:9-13. 2. Ophthalmology 2002; 109:584-7 3. Archives of Ophthalmology 2005; 123(3): 399-401. 4. Eye 2005; 19(6): 715-7.
The contents are not to be reproduced in part or in whole, without prior written approval from the editor. Whilst every effort is made in compiling the content of this publication, the publishers, editors and authors accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinions or statements. The mention of any product by the authors does not imply any official endorsement of the product by the Health Sciences Authority. Copyright 2005 Health Sciences Authority of Singapore. All Rights Reserved.
HSAs recommendations on cycloxygenase-2 (COX-2) selective and non-selective nonsteroidal anti-inflammatory drugs (NSAIDs)
HSA convened an expert advisory committee meeting in April 2005 to review the risk-benefit balance of COX-2 selective and non-selective NSAIDs following recent concerns on the cardiovascular safety of these drugs. The exper t recommendations (which exclude aspirin) were issued to our healthcare professionals on 28 April 2005. Below are the highlights: All COX-2 selective and non-selective NSAIDs should be prescribed at the lowest effective dose and the duration of treatment should be periodically reviewed and kept as short as possible; All COX-2 selective and non-selective NSAIDs should not be prescribed in patients who have recently undergone coronary artery bypass graft (CABG) surgery and revascularisation procedures; The benefits and risks of celecoxib and etoricoxib should be carefully assessed before they are prescribed to any individual patient, taking into consideration other available therapeutic options. Celecoxib or etoricoxib may be useful for patients who cannot tolerate or do not respond to other NSAIDs; Celecoxib or etoricoxib should not be prescribed in patients with established ischaemic heart disease, stroke or congestive heart failure; Caution should be exercised when prescribing celecoxib or etoricoxib to patients with risk factors for heart disease such as hypertension, hyperlipidaemia, diabetes and smoking or patients with peripheral arterial disease; Etoricoxib should not be prescribed in patients with hypertension whose blood pressure has not been adequately controlled. Careful monitoring of blood pressure is advised for patients taking etoricoxib as some data suggests that it may be associated with more frequent and severe effects on blood pressure than some other COX-2 selective and non-selective NSAIDs, particularly at high doses; All COX-2 selective and non-selective NSAIDs should be prescribed with care in elderly patients because of the possible risk of renal toxicity; Physicians are also advised to consider the use of gastroprotective agents for patients who are at a high risk of developing gastrointestinal complications whilst on COX-2 selective and non-selective NSAIDs. Patients at high risk would include those who are above 65 years old, those with previous history of peptic ulcer disease or peptic ulcer disease with complications, those who are on aspirin, high dose steroids or anticoagulants, and those who need multiple or high dose NSAIDs.